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Abstract
Introduction A novel approach of ion mobility tandem
mass spectrometry (IMS-MS/MS) is applied to analysis of
human glycourinome to obtain carbohydrate pattern data of
congenital disorders of glycosylation patient. Overlapping
of the complex carbohydrate mass range landscape has
been highly reduced upon IMS-MS procedure, allowing
more efficient identification by mapping and sequencing of
glycan precursor ions, following their separation by
mobility, according to difference in drift time through the
traveling wave IMS cell. Intact and truncated N- and O-
glycan structures modified by sialylation and fucosylation
were identified according to their drift time separated
molecular ions and submitted to fragmentation in a narrow
mass window.
IMS CID MS/MS Analysis The fragmentation spectra
generated from the IMS separated precursor ions contain
series of fragment ions maintaining the same mobility as
their parent ions, and the assignment accuracy can be
significantly enhanced.
Conclusion According to the specific fragment ion pat-
terns, carbohydrate epitopes described to be involved in
pathological processes were assigned. A high potential of
this glycomics-based strategy for clinical applications can
be presented.
Keywords Glycomics . Glycoconjugates . IMSMS .
Congenital disorders of glycosylation
Introduction
Congenital disorders of glycosylation (CDG) are a large
family of genetic diseases resulting from defects in the
synthesis of glycans and in the attachment of glycans to
lipids and proteins. These disorders cause a wide range of
clinically relevant human diseases with different, some-
times diffuse, clinical pictures. There are currently 12
defined N-, seven O- and three N- and O-glycosylation
defects due to defects in proteins with glycosyltransferase
or transport function already identified [1]. For a growing
group of patients with unidentified defects, but typical and
atypical clinical presentations in CDG, there is a high need
for an increase in the speed and accuracy of diagnostics in
order to design rational therapeutic suggestions in as short a
time span as possible.
The alteration of glycan patterns related to CDG defects
is reflected in the patients’ serum, which can be analyzed
for glycosylation patterns of glycoproteins, according to
proteomics-based protocols [2]. However, urine as a rich
source of metabolic structures renders an excellent oppor-
tunity for noninvasive sample diagnostics. Carbohydrate
patterns of CDG patients’ urine were investigated by us
using distinct glycomics-based strategies to explore the
feasibility of protocols and their potential for unique
structure discovery and clinical applications [3–6]. Compo-
nents of these highly complex mixtures depict different
levels of modifications by sialylation and fucosylation. A
high number of intact and truncated N- and O-glycan
structures were revealed by high resolution mass spectrom-
etry and correlated to the structures deposited in the
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databases [4]. Using a novel approach of ion mobility mass
spectrometry (IMS-MS), overlapping of the carbohydrate
mass range landscape was shown to be highly reduced,
allowing development of strategies for more efficient
identification by sequencing the glycan precursor ions,
following their separation by their mobility, or drift time,
through the traveling wave IMS cell [3]. The fragmentation
data obtained clearly demonstrate that carbohydrate epito-
pes can be de novo identified by this type of bioanalysis
rendering an efficient novel tool for glycomics to be
introduced to the CDG research and be applied to clinical
samples. In the following investigation, monosialylated
glycoforms from urine and their terminal epitopes were
identified by IMS and automatic data assignment to be
correlated with those described in carbohydrate databases
for comparison of their possible function.
Materials and Methods
Materials and Sample Preparation
Materials Methanol was obtained from Merck (Darmstadt,
Germany) and used without further purification. Graphi-
tized carbon powder for the graphitized carbon cartridge
preparation was collected by dismantling commercially
available Active Charcoal MicroTip Columns 25-100 µl
(Harvard Apparatus Inc). AG50 (H+) resin was purchased
from Bio-Rad (Richmond, CA, USA). Distilled and
deionized water (Mili-Q water systems Millipore, Bedford,
MA, USA) was used for the preparation of the sample
solutions.
CDG urine sample The sample investigated in this study
was a native glycoconjugate mixture from the urine of
patient K.L. suffering from symptoms assigned to the
congenital disorder of glycosylation (CDG). For isolation
of components, the patient’s urine was filtered and
submitted to a first gel filtration chromatography step on
Biogel P2 followed by several chromatography stages as
described previously [4, 5]. The fraction M3 from the
patient K.L. was used in the present study.
Desalting of glycoconjugate mixtures Prior to analysis by
mass spectrometry, the fraction M3 containing a mixture of
glycoconjugates was purified by homemade graphitized
carbon cartridges as described previously [7] and desalted
by AG50 (H+) resin.
Mass spectrometry All measurements were performed on a
Synapt high-definition mass spectrometry (HDMS) system
(Waters, Manchester, UK). The Synapt HDMS is a hybrid
quadrupole-triwave IMS-oa-TOF device. Gas-phase ions
were generated by nano-electrospray ionization in the
negative ion mode, passed through a quadrupole into the
triwave cell where the ions were separated according to
their mobility, and finally transferred to the oa-TOF mass
analyzer [3]. Ion source conditions were optimized to
minimize in-source fragmentation. DriftScope™ Mobility
Environment software was used for ion mobility data
visualization and manipulation. Instrumental control and
mass spectra acquisition were operated by Waters Mas-
sLynx 4.1 software.
Collision-induced dissociation (CID) structural analysis
of selected ionic species was performed by transfer T-Wave
fragmentation [3]. The fragmentation pattern of sequenced
glycoconjugates was assigned according to nomenclature
introduced by Domon and Costello [8].
Data interpretation The computer algorithm for mass
spectrometry data interpretation was developed by using
Borland Delphi 7 for Windows (Borland) [3]. All compu-
tational assignments have been performed within the mass
accuracy range of 0–25 ppm.
Glycan database Consortium for Functional Glycomics
(http://www.functionalglycomics.org, 2008) and Glycosuite
DB (https://tmat.proteomesystems.com/glycosuite, 2004)
glycan databases has been used for correlation with
proposed compositions by searching of structural informa-
tion, such as the type and the number of monosaccharide
building blocks. The list of previously described oligosac-
charide structures related to the imported composition was
generated as the output, providing information about the
sample source, methods of structural elucidation, and the
corresponding references.
Results
IMS-MS Glycoscreening of the KLM3 CDG Sample
Mapping and sequencing of monosialylated free and amino
acid-linked glycans in the urine of the CDG patient K.L.
has been probed in the fraction KLM3 to identify the type
of glycans involved, their branching patterns, and sialyla-
tion attachment. Analyzed in the negative ion MS mode
using a nanoESI oa-TOF mass spectrometer more than 100
singly, doubly, and triply charged ions has been observed
(Fig. 1). Three ubiquitous singly charged ion species at m/z
632.21, 673.22, and 876.30 assigned previously to Neu-
AcHex2, NeuAcHexHexNAc, and NeuAcHexHexNAc2,
respectively, were present at high abundance 40–100%,
but the majority of the ionic species, with highly over-
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lapping isotopic envelopes, were at or below 15%,
substantially hindering the tandem MS identification by
mapping and sequencing. As already reported, the intro-
duction of IMS as an additional dimension prior to mass
analysis allows effective separation of molecular ions in the
gas phase according to their charge, shape, and size [3].
Briefly, the ions are separated by their mobility through the
dense gas-filled traveling wave and, subsequently, mass
analyzed by the oa-TOF. Plotting the ions drift time versus
their m/z values, it can be observed that the signal is
distributed into three distinct nested areas, A, B, and C, based
upon their m/z and drift time relationship. These nested sets
correspond to the singly, doubly, and triply charge ions,
respectively (Fig. 1, inset). Selection of these regions and
maintaining their m/z and drift times produce mass spectra
containing predominantly singly, doubly, and triply charged
ion populations. These ions previously overlapped in the
TOF MS acquisition are now separated and localized into
the regions A, B, and C (Fig. 2). The ions with the signal-
to-noise ratio significant for the determination of isotopic
distribution are selected and submitted for automated
compositional analysis calculation.
The singly charged ion population obtained by selecting
region A (Fig. 1a) exposed the presence of at least 62
distinct ionic species, mostly below 15% abundance. Close
inspection of the mass spectrum acquired upon IMS
separation revealed a significant improvement in the
signal-to-noise ratio, as illustrated for the mass range
1500–2000 Da. The data that acquired overall mobility
drift times show only three ions at m/z 1565.57, 1727.60,
and 1862.88 (Fig. 1), where in the same m/z range of the
singly charged spectrum acquired from region A, six
additional species at m/z 1548.70, 1768.64, 1846.84,
1878.82, 1884.87, and 1930.65, respectively, can be easily
detected (Fig. 2a). Consideration of the established N-glycan
biosynthetic pathways allows the composition of ions at m/z






H]−, respectively and proposed to represent free N-glycans
without Asn attachment at the reducing end. Computational
analysis of all singly charged species in the region A ion
population allowed the compositions of ~67% of the selected
ions to be accomplished. The majority of the species were
proposed to represent free oligosaccharides, except 11 ionic
species identified by calculation as O-glycans linked either to
Ser, Thr, ThrPro, or SerThr (Table 1).
All doubly charged ions obtained by averaging over
region B were low abundant at the level of relative intensity
below ~12% (Fig. 2b). According to the compositional
analysis, 15 species out of 58 were assigned to free
oligosaccharides (Table 1). Three doubly charged ions at
m/z 758.25, 839.29, and 1094.86 were proposed to






respectively. Four doubly charged O-glycan species were
proposed according to the compositional analysis to be
linked at their respective reducing termini to Thr, Ser, Ser-
Thr, or Thr-Pro. These are the ionic species detected at m/z
Fig. 1 Negative ion mode
nanoESI oa-TOF MS of the
fraction M3 obtained from urine
of the patient KL after gel
permeation chromatography.
Spectrum was acquired from the
TIC chromatogram over all mo-
bility drift times. Inset: plot of
the drift time vs. m/z values for
the negative ion mode nanoESI
oa-IMS-TOF MS. Ions have
been distributed onto areas of
predominantly singly (A), dou-
bly (B), and triply (C) charged
ionic species (selected by
dashed lines). XIC chromato-
grams A, B, and C were gener-
ated from the corresponding
area
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2−, and [NeuAcdHexHex3 Hex-
NAc4ThrPro-2H]
2−, respectively. In the doubly charged pool,
the ions detected in the abundance range of 8–12% at m/z
469.15, 624.26, 930.89, and 1139.94 could not be assigned
to any glycoconjugate structures; but, according to their CID
MS/MS data, they could be assigned as collagen peptides
containing a common Gly-Leu/Ile-Pro repeat (data not
shown).
The data from region C produced 18 triply charged
species with distinct isotopic distribution that were utilized
for compositional analysis (Fig. 2c) and showed only six
ionic species representing glycoconjugates (Table 1). Ionic




3−, respectively. On the other hand,
triply charged ions at m/z 791.94, 845.96, 913.66, and
967.67 could be simultaneously assigned to free oligosac-














respectively (Table 1). The most intensive triply charged
ions detected at m/z 759.66 below 2% abundance were
assigned to a collagen peptide with Gly-Leu/Ile-Pro repeat
(data not shown).
Thus, in total 138 ionic species with distinct isotopic
distribution have been detected by IMS oa-TOF MS
approach, and 47 singly and multiply charged species that
previously overlapped became well separated using this
approach.
Fig. 2 Negative ion mode
nanoESI oa-IMS-TOF MS of
the sample KLM3 acquired
over: a XIC chromatogram
A, b XIC chromatogram B,
and c XIC chromatogram
C (Fig. 1, Inset)
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Table 1 Computer-assisted assignment of the major peaks detected in KLM3 sample by the negative ion nanoESI IMS oa-TOF MS
No. [M-H]- [M-2H]2- [M-3H]3- Proposed Composition MWf Referencesg
1 496.18 HexHexNAcAsn 497.19 –
2 544.20 Hex2HexNAc 545.20
i
3 602.21a HexHexNAcThrPro 581.24 –
4 599.21 NeuAc2 600.20 –
5 632.21 NeuAcHex2 633.21 [16, 17]
6 655.23b NeuAcHexHexNAc 674.24 [16–23]
673.22
7 714.26 NeuAcHexNAc2 715.27
i
8 769.26a Hex2HexNAc2 748.27 [24, 25]
9 760.27 NeuAcHexHexNAcSer 761.27 [26–28]
764.25c
10 774.29 NeuAcHexHexNAcThr 775.29 [26–28]
778.26c
11 809.25b Hex5 828.27 –
12 819.29 NeuAcdHexHexHexNAc 820.30 h
13 835.29 NeuAcHex2HexNAc 836.29 [29]
14 873.34 436.16 dHexHexNAc3Thr 874.35 –
15 876.30 NeuAcHexHexNAc2 877.32 [19, 30]
16 481.66 NeuAc2HexHexNAc 965.33 [16, 19–23, 26–28, 31, 32]
17 981.34 NeuAcdHexHex2HexNAc 982.35
i
18 997.33 NeuAcHex3HexNAc 998.34
i
19 1038.36 NeuAcHex2HexNAc2 1039.37 [19, 22, 33]
20 1079.39 NeuAcHexHexNAc3 1080.40
i
21 1125.38 562.19 NeuAcHex2HexNAc2Ser 1126.40 –
22 1143.38 NeuAcdHexHex3HexNAc 1144.40 –
23 1152.41 575.69 NeuAc2HexHexNAcSerThr 1153.41 –
24 1184.42 609.68d NeuAcdHexHex2HexNAc2 1185.43
i
25 1200.42 617.69d NeuAcHex3HexNAc2 1201.42 [10, 17]
26 1241.45 NeuAcHex2HexNAc3 1242.45
i
27 1362.47 680.72 NeuAcHex4HexNAc2 1363.48 [10, 11]
698.71d
28 1369.49b NeuAcdHexHex2HexNAc3(-H2O) 1388.51
i
29 1403.49 719.22d NeuAcHex3HexNAc3 1404.50
i
30 744.75b NeuAcdHexHex4HexNAc2 1509.53 –
31 758.25 NeuAcHex3HexNAc3Asn 1518.54 –
32 1565.57 800.24d NeuAcHex4HexNAc3 1566.55 [10, 34, 35]
33 803.76e NeuAcdHexHex2HexNAc4 1591.59 –
812.75d
34 839.29 NeuAcHex4HexNAc3Asn 1680.60 –
35 1727.60 881.27d NeuAcHex5HexNAc3 1728.61 [10, 11, 34, 35]
36 1768.64 NeuAcHex4HexNAc4 1769.63
h
37 1930.65 982.81d NeuAcHex5HexNAc4 1931.69 [13, 34, 36]
38 974.88 NeuAcdHexHex3HexNAc4ThrPro 1951.74 –
39 675.57 NeuAcdHexHex4HexNAc4Asn 2029.74 –
40 1055.85d NeuAcdHexHex5HexNAc4 2077.74 [13, 36]
41 1094.86 NeuAcdHexHex5HexNAc4Asn 2191.79 –
42 1150.92 NeuAcdHexHex4HexNAc6 2303.84 –
43 791.94 NeuAcHex4HexNAc7 2378.87 –
NeuAcdHex2Hex4HexNAc5Asn 2378.87 –
44 797.27 NeuAcdHexHex5HexNAc5Asn 2394.87 –
45 1199.93 NeuAcdHexHex7HexNAc4 2401.85 –
46 845.96 NeuAcHex5HexNAc7 2540.93 –
NeuAcdHex2Hex5HexNAc5Asn 2540.93 –
47 913.66 NeuAcHex5HexNAc8 2744.00 –
NeuAcdHex2Hex5HexNAc6Asn 2744.00 –
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IMS CID MS/MS Analysis
For the investigation of glycan structure by tandem MS
analysis, the overlapping of precursor ions represents a
significant obstacle since a mixture of fragment ions
originating from ions at the same or similar m/z values
does not deliver useful data for assignment. In the case of
overlapping ion envelopes of the singly charged species at




2−, respectively, the isotopic pattern of
the doubly charged ions is obscured by that of the singly
charged one (Fig. 3a), obstructing both the determination of
the monoisotopic m/z value and selection of the appropriate
Table 1 (continued)
No. [M-H]- [M-2H]2- [M-3H]3- Proposed Composition MWf Referencesg










f Calculated molecular weight of the proposed composition.
g References are related to glycoconjugates previously found in Homo sapiens urine as free molecular species or as glycans obtained by protein
deglycosylation.
h Glycoconjugates found in different organs from Homo sapiens urogenital system, besides urine.
i Glycoconjugates found in Homo sapiens from systems other than urogenital.
Fig. 3 a Expansion of the mass range at m/z 1196–1208 of the
negative ion mode nanoESI oa-TOF MS of the fraction KLM3,
acquired from TIC chromatogram over all mobility drift times; b
expansion of the mass range at m/z 1196–1208 of the spectrum
acquired from XIC chromatogram of singly charged distributed area
after IM separation; c Expansion of the mass range at m/z 1196–1208
of the spectrum acquired from XIC chromatogram of doubly charged
distributed area after IM separation; d Plot of the drift time vs. m/z
values for fragment ions obtained by CID of overlapped precursor ions
at m/z 1199.93 (left) and 1200.42 (right); e Total ion current
chromatogram with retained drift time of overlapped precursor ions
at m/z 1199.93 (left) and 1200.42 (right). Selected areas indicate
extracted ion current chromatogram A for the precursor ions at m/z
1200.42 and chromatogram B for the precursor ions at m/z 1199.93
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ion selection for fragmentation. Upon separation of the
overlapping precursor ions by ion mobility, CID fragmen-
tation using a transfer traveling wave gas cell, which is
located after the IMS gas cell, generates distinct sets of
fragments, as illustrated for ions at m/z 1200.42 and
1199.93 (Fig. 3b and c). The CID fragmentation of these
IMS separated precursor ions generates series of fragment
ions maintaining the same mobility as their parent ions
(Fig. 3d). These distinct drift time areas can be used to
generate individual chromatograms and, subsequently, mass
spectra (A and B, respectively), as shown in Fig. 3e.
The fragmentation spectrum representing the glycan
sequence of the singly charged precursor ions at m/z
1200.42 assigned to [NeuAcHex3HexNAc2-H]
− obtained
from drift time region A (Fig. 3e) is presented in Fig. 4.
According to the evidence of the 0,2A6 cross-ring fragment
ions at m/z 1099.36, the free HexNAc residue at the
reducing end can be proposed [5]. The observed loss of
Δm = 131u and 161u from the parent ions allows
assignment of m/z 1069.42 and m/z 1039.35 as 2,4A6 and
0,3A6 cross-ring fragment ions, respectively, and proposes
further extension of the reducing end only at the “C4”
position of the HexNAc. The loss of Δm = 60u, detected at
m/z 937.32 from the C5 fragment at m/z 997.32, indicates
that the next structural element elongating the reducing
HexNAc is the Hex and can be assigned to 0,2A5 fragment
ions. Further inspection of the spectrum revealed the
presence of an ion series, indicating the existence of a
NeuAcLacNAc motif in the structure. Ions at m/z 290.09,
452.14, 655.22, and 673.23 compositionally proposed as
NeuAc(-H2O), NeuAcHex, NeuAcHexHexNAc(-H2O), and
NeuAcHexHexNAc could be assigned to B1, B2, B3, and
C3 glycosidic fragments. Taking into account the presence
of Z2, Y2, B4, and C4 at m/z 364.13, 382.14, 817.27, and
835.28, respectively, as well as the rules of glycan
assembly, the potential structural candidate was proposed
as a truncated sialylated N-glycan NeuAc(α2–6)Gal(β1–4)
GlcNAc(β1–2)Man(α1–3/6)Man(β1–4)GlcNAc with only
one antenna, where the α2–6 linkage between NeuAc and
Gal was proposed according to the diagnostic 0,4A2-CO2
cross-ring fragment being present at m/z 306.12 [9].
Searching the glycan database (http://www.functionalgly
comics.org, 2008; https://tmat.proteomesystems.com/glyco
suite, 2004) allowed correlation of the proposed structure
with the one previously found in the urine of a patient
suffering from infantile sialidosis, type II (dysmorphic) [10,
11]. On the other hand, a number of ions which cannot
originate from the proposed structure, such as NeuAcHex-
HexNAc2 at m/z 876.35 or NeuAcHex2 at m/z 632.21, were
also found in the spectrum, indicating the existence of an
additional structural isomer with the same composition.
The fragmentation pattern of the doubly charged
precursor at m/z 1199.93 separated by IMS and obtained
by selecting the data shown in region B (Fig. 3e) can be
assigned to [NeuAcdHexHex7HexNAc4–2H]
2− (Fig. 5a).
Inspection of the MS/MS spectrum revealed the presence
of fragment ions corresponding to NeuAc(-H2O) at m/z
290.10, NeuAcHex at m/z 470.17, and NeuAcHexHex
NAc at m/z 673.26. Besides the NeuAcLacNAc antennae
terminal, a NeuAcLea/x antennae structure was present
according to the presence of the fragment ion at m/z
819.35. Thus, taking into account the biosynthetic rules of
N-glycan antennae assembly as well as the evidence of
the existence of truncated glycans in the urine, the
structure of this species has been proposed, as summa-
rized in Fig. 5b.
Fig. 4 Fragmentation pattern of
the singly charged precursor
ions at m/z 1200.42. The spec-
trum was obtained by averaging
over XIC chromatogram A
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Ions at m/z 809.30 assigned to Hex5(-H2O) and m/z
1038.43 assigned to NeuAcHex2HexNAc2 were considered
as “D” type and C4a fragments, respectively, originating
from the potential hybrid-type N-glycan isomer (Structure
B, Fig. 5b). The double loss of a HexNAc unit from the
parent ions detected at m/z 1994.72 indicates the absence of
the core Fuc at the reducing end, and together with ions,
indicating the presence of NeuAcLea/x antennae can support
structural isomer D (Fig. 5b). Ions at m/z 1143.54 assigned
to NeuAcdHexHex2HexNAc can be considered as “D+
H2O” type fragment of the structural isomer, where the
NeuAcLea/x antennae is distributed at Man6 of the N-
glycan core region (Structure C, Fig. 5b). Among the
proposed structures depicted, only the structure A (Fig. 5b),
supported by the presence of C4a at m/z 1200.46 has been
found in the glycan database with a nonspecified source of
origin (http://www.functionalglycomics.org, 2008).
The doubly charged precursor ions at m/z 1055.85
assigned to [NeuAcdHexHex5HexNAc4-H+Cl]
2− represent
another example of sialylated and fucosylated oligosaccha-
ride found in the urine of CDG patient. To obtain a distinct
series of fragment ions related only to the doubly charged
precursors, IMS T-Wave transfer fragmentation analysis has
been performed, and the spectrum acquired over the drift
time range from 4.0 to 7.5 ms of the TIC chromatogram
(Fig. 6a, inset). According to biosynthetic rules of glycan
assembly and taking into account the ratio of monosaccha-
ride units in the proposed composition, potential structural
Fig. 6 a Negative ion mode
nanoESI IMS oa-TOF MS/MS
of the doubly charged precursor
ions at m/z 1055.85. Fragmen-
tation spectrum obtained by av-
eraging over XIC chromatogram
(Inset, dashed line); b structural
candidates proposed according
to the rule of glycan biosynthe-
sis and by the presence of
diagnostic fragment ions
Fig. 5 a Negative ion mode
nanoESI IMS oa-TOF MS/MS
of the doubly charged precursor
ions at m/z 1199.93. Fragmen-
tation spectrum obtained by av-
eraging over XIC chromatogram
B (Fig. 3e) after IM separation.
b Structural candidates proposed
according to the rule of glycan
biosynthesis and by the presence
of diagnostic fragment ions
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candidates could be proposed as monosialylated N-glycans
with one peripheral or one core fucosylation. The presence
of a NeuAcLacNAc antenna has been monitored by the
diagnostic fragment ions assigned to NeuAcHexHexNAc
detected at m/z 673.27. Fragment ions detected at m/z
819.29 and assigned to NeuAcHexHexNAc indicate a
potential NeuAcLea/x antennae structure, supporting the
assumption of peripheral fucosylation. Thus, several struc-
tural isomers or isobars could be related to the precursor
ions (Fig. 6b). The presence of diagnostic C4 and “D” type
fragment ions [12] allows to determine the distribution of
antennae at the pentasaccharide core of potential structural
candidates. Fragment ions at m/z 688.23 and 835.28
assigned to Hex2HexNAc and NeuAcHex2HexNAc has
been considered as “D” and C4a, respectively, of the
monosialylated biantennary N-glycan with core Fuc, where
NeuAcLacNAc antenna is attached to Man3 of the core
region (Structure A, Fig. 6b). The attachment of Neu
AcLacNAc antenna at Man6 of the core region has been
specified by the presence of “D+H2O” and C4b fragment
ions at m/z 997.34 and 544.19, respectively (Structure B,
Fig. 6b). On the other hand, fragment ions at m/z 544.19
can also be originated as C4b from the Structure C (Fig. 6b),
supported by “D” and “D+H2O” at m/z 1125.39 and
1143.39, respectively. The fourth structural candidate,
isobaric with previous ones, could be proposed and
assigned according to glycan biosynthesis rules to a hybrid
type monosialylated N-glycan (Structure D, Fig. 6b). C4a
fragment ions detected at m/z 1184.42 and assigned to
NeuAcdHexHex2Hex2 support this assumption. A correla-
tion of the Structure A with that previously discovered in
the urine of a male donor by monosaccharide analysis and
1H NMR [13] has been done by glycan database search
(http://www.functionalglycomics.org, 2008).
Thus, according to the analysis performed in this study,
the present status of the KLM3 sample composition reveals
Table 2 Proposed structures carrying Sialyl T and Sialyl Lea/x associated epitopes found in KLM3 urinary sample
  Proposed Structure a) Composition MW b) Antigen
1 NeuAcHexHexNAc 674.24 Sialyl T




















a Symbolic presentation of glycoconjugate structures, where figures represent monosaccharides: ■ (GlcNAc), □ (GalNAc), (Gal), ○ (Man), ◊
(NeuAc), △ (Fuc). Glycosidic linkages are schematically presented by differently oriented lines: ― (1–4), / (1–3), \ (1–6) and | (1–2). For
undefined type of glycosidic linkage dotted line was used.
b Calculated molecular weight of the proposed composition.
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30 proposed structures which were found to be associated
with detected ionic species. Upon classification of these 30
glycoconjugate structures, the expression of SiaLea/x and
Sialyl T terminal epitopes in both N- and O-linked glycan
components could be postulated (Table 2). These epitopes
have been previously observed in malignant tissues in
different organs of human bodies, where glycosylation
changes caused by cancer and/or inflammation diseases are
the probable cause for their overexpression [14].
Since the significantly increased degree of core fucosyla-
tion of biantennary N-glycans as compared to normal has
been reported in all so far known subtypes of CDG I [15], the
validation of fucosylated oligosaccharides in the urine of
CDG patient represents a potential direction for biomarker
search.
Conclusions
Using the novel approach of ion mobility, separation
coupled with tandem mass spectrometry intact and truncat-
ed N- and O-glycan structures from CDG patients’ urine
can be de novo identified by mapping and sequencing. By
automatic assignment, the composition of single species
from the IMS-separated spectra, with reduced complexity,
were shown to be accessible for structure correlations to
those in databases. Through the use of IMS, the over-
lapping carbohydrate m/z landscape was highly reduced in
given window, allowing the development of a highly
efficient identification procedure by sequencing precursor
ions, using transfer CID fragmentation after separation by
IMS. Combining it with a previously proposed automated
calculation procedure provides an efficient novel tool for
glycomics to be introduced, and this can readily be applied
to CDG research and clinical samples. Accordingly,
different levels of sialylation and fucosylation can be
analyzed and assigned to truncated and untruncated glycan
structures containing possible clinically relevant epitopes.
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